Current circulating biomarkers, such as Tg or TgAb, are routinely used in postoperative monitoring; however, at the preoperative stage, they cannot distinguish between benign and malignant neoplasms or between low- and high-risk malignant lesions. This evidence concerns the gene TG and cancer.